Chi Kong Li
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies (NCT06462248) | Chi Kong Li | 2024-06-01 |
Track Chi Kong Li automatically
Every clearance here is in the API, with alerts when new ones post.